Aker Biomarine AS (AKBM)
Oslo Stock Exchange · Norway · prices in NOK · close of 5 Oct 2026
Key indicators
| Last close | NOK 122.00 |
|---|---|
| 52-week range | 78.80 – 136.40 |
| Return, 1 month / 3 months | −9.9% / +25.0% |
| Return, 1 year / 3 years | +32.8% / +477.2% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 46 |
| Volatility (1 year) | 33.3% |
| Worst drawdown (1 year) | -17.1% |
| Average daily value traded | 23.14M NOK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Aker BioMarine is a Norwegian company that harvests krill in Antarctic waters and turns the catch into ingredients for nutrition and animal feed. It produces krill oil, sold as a dietary supplement for people, and krill meal and other krill-derived ingredients used in feed for farmed fish. The company is based in Norway and serves customers in the human health and aquaculture markets around the world.
Aker Biomarine AS trades under the code AKBM on the Oslo Stock Exchange in Norway, with its price quoted in Norwegian kroner (NOK). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Aker Biomarine AS (AKBM) trades on the Oslo Stock Exchange in Norway. It last closed at NOK 122.00 on 5 October 2026.
Its price-based Market X-Ray is 77 out of 100 (a strong price profile), ranking 25 of 294 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 32.8% and over the last three months it rose 25.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Oslo Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 77 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.5% | ||
| From 52-week high | -9.9% | ||
| Momentum | 82 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 23.2% | ||
| 6-month return | 18.0% | ||
| 12-month return, skipping the last month | 44.4% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 33.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.1% | ||
| Liquidity | 82 · Strong | Trades actively. | |
| Average daily value traded | 23.14M NOK | ||
| Zero-volume days | 3.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +1.2% |
|---|---|
| 1 month | −9.9% |
| 3 months | +25.0% |
| 6 months | +14.0% |
| 1 year | +32.8% |
| 3 years | +477.2% |
| 5 years | – |
Signals
| 50-day / 200-day average | 123.00 / 106.52 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.73 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Sep 2024 | NOK 45.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Oslo Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.